Download Files:
Etrinabdione
$135 – $480
Products Details
Product Description
– Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2].
Web ID
– HY-128872
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C28H35NO3
References
– [1]Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64.|[2]Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092.
CAS Number
– 1818428-24-8
Molecular Weight
– 433.58
Compound Purity
– 98.56
SMILES
– O=C1C(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(C(NCC3=CC=CC=C3)=C1CCCCC)=O
Clinical Information
– Phase 2
Research Area
– Metabolic Disease; Inflammation/Immunology
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Cannabinoid Receptor;HIF/HIF Prolyl-Hydroxylase;PPAR
Isoform
– CB2;PPARγ
Pathway
– Cell Cycle/DNA Damage;GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling;Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
